Combining evidence for access to and benefits from antiretroviral treatment to inform planning

AIDS. 2008 Jul:22 Suppl 1:S121-2. doi: 10.1097/01.aids.0000327632.08093.bd.

Authors

Editorial Steering Committee¹; Richard Marlink, Steven Forsythe, Stefano M Bertozzi, Debbie Muirhead, Marionette Holmes, Jeffrey Sturchio

Affiliation

¹ Harvard School of Public Health, Boston, MA, USA. marlink@hsph.harvard.edu

PMID: 18664943
DOI: 10.1097/01.aids.0000327632.08093.bd

No abstract available

MeSH terms

Anti-Retroviral Agents / economics
Anti-Retroviral Agents / supply & distribution*
Anti-Retroviral Agents / therapeutic use
Cost-Benefit Analysis
Developing Countries*
HIV Infections / drug therapy*
HIV Infections / economics
Health Planning / methods*
Humans
Quality-Adjusted Life Years

Substances

Anti-Retroviral Agents